fda green list glp-1 import alert 66-80 Compounded weight-loss and hormone drugs are booming, but experts say regulators have little visibility into who is taking them or what side effects they may be causing. ⁠ ⁠ Critics warn that 503A GLP-1 Compounding Compliance, Trends,

This occurs because the hormone alters the uterine lining, sometimes causing irregular shedding

Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study

22,23 Bariatric surgery is another option for inducing weight loss in obese individuals if the aforementioned treatment strategies fail, although patients often develop post-surgery complications requiring further therapeutic intervention

No language restrictions were applied

According to the FDA, the agency has received reports of gastroparesis with semaglutide and liraglutide, some of which documented the adverse event as not recovered after discontinuation of the respective product at the time of the report. The FDA statement qualified the report by clarifying that gastroparesis can be a complication of diabetes